The risk of @entity1504 after @entity542 ( @entity542 ) is low. Despite this, a computed tomography (CT) scan is generally recommended for all @entity1 following @entity542 . Admission for clinical observation is a secondary management option when a CT scan is unavailable or is judged inappropriate. Both alternatives are associated with disadvantages and several attempts at refining existing guidelines for @entity542 management have been proposed as a means of reducing CT and/or admission. However, they are based on potentially unreliable @entity1 history and clinical examination and, furthermore, may be compromised by @entity1 factors such as intoxication. Clinical studies from several research groups have shown the potential of brain biomarker @entity4483 in this @entity1 category. The specificity of @entity4483 is poor, but a high sensitivity for brain damage effectively rules out relevant complications after @entity542 . Used in conjunction with existing guidelines, serum levels of @entity4483 can accurately identify @entity1 who do not need a CT scan after @entity542 . Based on 6 prospective studies comprising almost 2,000 @entity1 with @entity542 , the sensitivity and negative predictive value of @entity4483 for CT findings were 98.2% and 99.5%, respectively, and for clinically relevant intracranial complications 100% and 100%, respectively. Integration of @entity4483 within existing management routines can reduce the need for CT scans by 30%, resulting in improved and more efficient @entity1 care.

A new objective method for CT triage after @entity542 --serum XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity542 :: ('MESH:D006259', 'Disease') :: ['minor head injury', 'MHI'] @entity4483 :: ('6285', 'Gene') :: ['S100B'] @entity1504 :: ('MESH:D002561', 'Disease') :: ['acute intracranial complication']
@entity4483 :: (6285,Gene) :: ['S100B']
